Amgen gets Japanese authorization for migraine drug

The Japanese health authorities have given sales and marketing of Amgen's migraine drug Aimovig in the country the green light.

Photo: Mark J. Terrill/AP/Ritzau Scanpix

The Japanese health authority Pharmaceuticals and Medical Devices Agency (PMDA) has approved the migraine drug Aimovig produced by US biopharmaceutical company Amgen for sales and marketing in Japan, according to an Amgen press release.

Aimovig is a calcitonin gene-related peptide (CGRP) inhibitor drug that targets the CGRP receptor, which is associated with migraines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs